Kailera Therapeutics reported a net loss of $285.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $256.6 million. During the period, the company completed its initial public offering, raising $662.0 million in net proceeds and ending the quarter with $1.03 billion in total stockholders' equity.
Kailera Therapeutics reported Q3 2026 financial results, ending the period with $847.4 million in cash and equivalents to support operations into mid-2028. The company highlighted significant clinical progress, including the full enrollment of its KaiNETIC Phase 3 program for injectable ribupatide and plans to initiate a Phase 3 program for oral ribupatide in 1H 2027.
Term
Q3 2026
“Kailera was built to bring new medicines to people living with obesity, and our strong execution this quarter reflects that commitment. All four of our product candidates are on track to deliver important clinical milestones in 2027, including the initiation of our Phase 3 trial for ribupatide oral and the data readout from the ribupatide injection high-dose Phase 2b trial. With the ribupatide franchise’s category-leading potential at the core of a diversified portfolio, and a balance sheet that supports multiple value-creating inflection points into mid-2028, I am proud of our team and energized by what we aim to deliver for people living with obesity.”
Ron Renaud, President and Chief Executive Officer of Kailera